Show simple item record

dc.contributor.authorAjore, Ram
dc.contributor.authorRaiser, David
dc.contributor.authorMcConkey, Marie
dc.contributor.authorJöud, Magnus
dc.contributor.authorBoidol, Bernd
dc.contributor.authorMar, Brenton
dc.contributor.authorSaksena, Gordon
dc.contributor.authorWeinstock, David M
dc.contributor.authorArmstrong, Scott
dc.contributor.authorEllis, Steven R
dc.contributor.authorEbert, Benjamin L
dc.contributor.authorNilsson, Bjorn
dc.date.accessioned2017-06-15T14:44:21Z
dc.date.available2017-06-15T14:44:21Z
dc.date.issued2017-03
dc.date.submitted2017-01
dc.identifier.issn1757-4676
dc.identifier.issn1757-4684
dc.identifier.urihttp://hdl.handle.net/1721.1/109887
dc.description.abstractHeterozygous inactivating mutations in ribosomal protein genes (RPGs) are associated with hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans and model organisms. Here we performed a large‐scale analysis of cancer genome data to examine the frequency and selective pressure of RPG lesions across human cancers. We found that hemizygous RPG deletions are common, occurring in about 43% of 10,744 cancer specimens and cell lines. Consistent with p53‐dependent negative selection, such lesions are underrepresented in TP53‐intact tumors (P ≪ 10⁻¹⁰), and shRNA‐mediated knockdown of RPGs activated p53 in TP53‐wild‐type cells. In contrast, we did not see negative selection of RPG deletions in TP53‐mutant tumors. RPGs are conserved with respect to homozygous deletions, and shRNA screening data from 174 cell lines demonstrate that further suppression of hemizygously deleted RPGs inhibits cell growth. Our results establish RPG haploinsufficiency as a strikingly common vulnerability of human cancers that associates with TP53 mutations and could be targetable therapeutically.en_US
dc.description.sponsorshipUnited States. National Institutes of Health (R01 HL082945)en_US
dc.description.sponsorshipUnited States. National Institutes of Health (P01 CA108631)en_US
dc.language.isoen_US
dc.publisherWiley Blackwellen_US
dc.relation.isversionofhttp://dx.doi.org/10.15252/emmm.201606660en_US
dc.rightsCreative Commons Attribution 4.0 International Licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.sourceEuropean Molecular Biology Organization (EMBO)en_US
dc.titleDeletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert withen_US
dc.typeArticleen_US
dc.identifier.citationAjore, Ram; Raiser, David; McConkey, Marie; J?ud, Magnus; Boidol, Bernd; Mar, Brenton; Saksena, Gordon et al. “Deletion of Ribosomal Protein Genes Is a Common Vulnerability in Human Cancer, Especially in Concert with TP53 Mutations.” EMBO Molecular Medicine 9, no. 4 (March 2017): 498–507 © 2017 The Authorsen_US
dc.contributor.departmentBroad Institute of MIT and Harvarden_US
dc.contributor.mitauthorEbert, Benjamin L
dc.contributor.mitauthorNilsson, Bjorn
dc.relation.journalEMBO Molecular Medicineen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsAjore, Ram; Raiser, David; McConkey, Marie; Joud, Magnus; Boidol, Bernd; Mar, Brenton; Saksena, Gordon; Weinstock, David M; Armstrong, Scott; Ellis, Steven R; Ebert, Benjamin L; Nilsson, Bjornen_US
dspace.embargo.termsNen_US
mit.licensePUBLISHER_CCen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record